Tanja Obradovic, Senior Advisor of Oncology Drug Development at HopeAI, Consultant, Oncology Drug Development at Arc Nouvel Clinical Development Consulting, and Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Chances to move into earlier line for HR-positive, HER2-negative breast cancer just got uncertain. Based on reported results of Phase III ASCENT-07 trial at SABCS2025.
It failed to significantly extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following endocrine therapy vs SOC chemo. OS data is immature and will be followed by failure of the primary objective of PFS opens gate to other ongoing competitors in this space.”
More posts featuring Tanja Obradovic.